Még nem toboroz
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· 4. fázis· University Hospital, Clermont-Ferrand· Forrás
Toboroz
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test
2025-521045-24-00· 3. fázis· Unicancer· Forrás
Még nem toboroz
Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease
NCT07284394· 3. fázis· UNICANCER· Forrás
Toboroz
Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study
NCT07616687· 4. fázis· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás
Toboroz
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
NCT07292012· 4. fázis· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás
Toboroz
Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab)
2023-506291-28-00· 3. fázis· Centre Leon Berard· Forrás
Toboroz
Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line treatment – A non-comparative, randomized phase II PANORAMIX GERCOR G-116 PRODIGE 105 study
2024-517766-41-00· 2. fázis· Association Gercor· Forrás
Toboroz
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
NCT06940661· 2. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Toboroz
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
NCT07044453· 2/3. fázis· University Hospital, Rouen· Forrás
Toboroz
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
NCT06346197· 3. fázis· Centre Leon Berard· Forrás
Contact: Raphaël COLLE, Dr
Toboroz
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
NCT06529718· 2. fázis· UNICANCER· Forrás
Még nem toboroz
Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer
NCT06999512· 2/3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Contact: Ecoline TRIBILLON (principal investigator)
Fut, nem toboroz
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer
2024-513122-27-00· 3. fázis· Daiichi Sankyo Inc.· Forrás
Toboroz
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
NCT05974774· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma
2024-516709-22-00· 2/3. fázis· Centre Hospitalier Regional Universitaire· Forrás
Toboroz
Short versus long antiplatelet therapy after TAVI
2023-508208-40-00· 2/3. fázis· Centre Hospitalier Universitaire De Caen Normandie· Forrás
Fut, nem toboroz
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Comparison of 3 RF Delivery Modes of the QDOT Catheter for Paroxymal Atrial Fibrillation (AF) Ablation
NCT06647251· Institut Mutualiste Montsouris· Forrás
Contact: Frederic SEBAG
Fut, nem toboroz
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)
NCT04262687· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás
Toboroz
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
NCT06333314· 2. fázis· UNICANCER· Forrás
Contact: Raphaël COLLE, MD
Toboroz
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
NCT06253611· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Contact: Emilie SOULARUE, MD
Toboroz
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· 3. fázis· Institut Gustave Roussy· Forrás
Toboroz
CARE1 Pragmatic Clinical Trial
NCT06364631· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Contact: Mostefa BENNAMOUN, md
Toboroz
DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study
NCT06059495· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Toboroz
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
NCT05787197· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Contact: David MLAKA, MD
Fut, nem toboroz
SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer
NCT05826509· 2. fázis· Institut Claudius Regaud· Forrás
Toboroz
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NCT05639413· UNICANCER· Forrás
Contact: Emilie SOULARUE, MD
Fut, nem toboroz
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
NCT05476796· 2. fázis· UNICANCER· Forrás
Fut, nem toboroz
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
NCT05462613· 2/3. fázis· Centre Hospitalier Universitaire de Besancon· Forrás
Fut, nem toboroz
An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma
2022-501463-40-01· 3. fázis· Servier Affaires Medicales· Forrás
Fut, nem toboroz
Balloon-Expandable Versus Self-expanding Transcatheter Heart Valve for Treatment of Symptomatic Native Aortic Valve Stenosis (BEST)
NCT05454150· University Hospital, Lille· Forrás
Toboroz
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
NCT06511648· 2. fázis· Spanish Oncology Genito-Urinary Group· Forrás
Toboroz
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT05528952· 2. fázis· Centre Hospitalier Universitaire de Besancon· Forrás
Contact: Emilie SOULARUE, Dr
Toboroz
TERTIO : Evaluation de l’intérêt de combiner un vaccin inducteur de CD4-Th1 dérivé de la télomérase avec un traitement par atezolizumab et bevacizumab chez des patients avec un carcinome hépatocellulaire non résécable : une étude de phase II randomisée preuve du concept
2022-500643-20-00· 2. fázis· CHUR Of Besançon· Forrás
Toboroz
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study
NCT04935853· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Contact: Christophe LOUVET, MD
Fut, nem toboroz
DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
2024-518244-20-01· 2. fázis· Queen Mary University Of London· Forrás
Fut, nem toboroz
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· 3. fázis· ARCAGY/ GINECO GROUP· Forrás
Toboroz
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
NCT05183984· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Fut, nem toboroz
MSI/dMMR tumors in perioperative setting
NCT04795661· 2. fázis· Centre Leon Berard· Forrás
Fut, nem toboroz
STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation
NCT04428944· McGill University Health Centre/Research Institute of the McGill University Health Centre· Forrás
Fut, nem toboroz
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.
NCT04730544· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Fut, nem toboroz
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
NCT03806309· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Fut, nem toboroz
Study comparing a metformin treatment to standard care to extend time without diabetes after bariatric surgery
NCT04581447· 3. fázis· Assistance Publique Hopitaux De Paris· Forrás
Fut, nem toboroz
Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO33)
2024-516649-38-00· 3. fázis· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Forrás
Toboroz
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
NCT04325425· 2. fázis· Centre Hospitalier Universitaire Dijon· Forrás
Fut, nem toboroz
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853· 3. fázis· AstraZeneca· Forrás
Toboroz
Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX (GEMFOX)
NCT04167007· 2/3. fázis· Assistance Publique Hopitaux De Paris· Forrás
Fut, nem toboroz
Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)
NCT04075981· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Showing 50 of 60.